Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
KLWS-V502
- Development stage
- Phase 3
- Lead developer
- Beijing Health Guard Biotechnology
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
KLWS-V502 is a recombinant nonavalent human papillomavirus (HPV) vaccine produced in Escherichia coli, targeting HPV types 6, 11, 16, 18, 31, 33, 45, 52, and 58. It induces neutralizing antibodies against these high-risk and low-risk HPV types to prevent associated premalignant lesions, genital warts, and cancers, particularly cervical cancer. Developed by Beijing Health Guard Biotechnology, it is administered intramuscularly in a 3-dose schedule and has been evaluated in Phase 1, 2, and 3 trials demonstrating non-inferior immunogenicity and comparable safety to GARDASIL® 9.[1][3][9][12][13]
- Other names
- Nonavalent HPV vaccine (E. coli)Recombinant nonavalent human papillomavirus vaccine (types 6, 11, 16, 18, 31, 33, 45, 52, 58)Beijing Health Guard nonavalent HPV vaccine
02
Targets
HPV L1 (Human papillomavirus L1 capsid protein)HPV11 L1HPV16 (Human papillomavirus type 16)HPV18 L1Human papillomavirus type 31 L1 capsid proteinHPV33 L1HPV45 L1HPV52 L1 (Human papillomavirus type 52 major capsid protein L1)HPV58 L1 (Human papillomavirus type 58 major capsid protein L1)HPV6 L1 (Human papillomavirus type 6 major capsid protein L1)
Beyond the preview
Go deeper on KLWS-V502.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on KLWS-V502.